Resources
7 Results (showing 1 - 7)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 5/10/2022 (updated 3/27/2024)
Background: Drug checking uses analytical chemistry technologies to report on the composition of drugs from the unregulated market to reduce substance use-related risks, while additionally allowing for monitoring and reporting of the supply. In the context of an overdose crisis linked to fentanyl, we used drug checking data to examine variability within the illicit opioid supply.
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 12/9/2019 (updated 3/28/2024)
Posted 9/18/2020 (updated 3/29/2024)
We have included information that will be relevant
to the broad range of HRSA RCORP-Planning grantees.
We encourage you to work through this packet section by
section, keeping in mind the timeline for final submission of
core grant deliverables.
Posted 9/18/2020 (updated 3/29/2024)
This is the template for the PIII MOU deliverable.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 5/17/2024
The resource LEVELING UP: A Guide for Optimizing the Impact of Your RCORP Consortium to Support Rural Recovery was developed by RCORP-TA and is designed to support RCORP project directors and teams in effectively structuring, leading, and managing consortia throughout the award period and beyond.